drugset / Trial / NCT03486561
Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)
NaSingle-groupOpen-labelTreatment
Summary
The rationale of MIDA trial is to determine efficacy and tolerability of ranolazine molecule among Pakistan population and obtain firsthand knowledge about the molecule ranolazine.
Timeline
- Start
- 2018-04-01
- Primary completion
- 2018-09-30
- Completion
- 2018-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranolazine | Small molecule | 500 mg | — |
| Subject | Ranolazine | Small molecule | 1000 mg | — |